HomeNTRA • NASDAQ
add
Natera Inc
Previous close
$169.36
Day range
$163.07 - $170.59
Year range
$53.62 - $171.95
Market cap
20.69B USD
Avg Volume
1.32M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 439.76M | 63.90% |
Operating expense | 311.08M | 34.10% |
Net income | -31.59M | 71.02% |
Net profit margin | -7.18 | 82.33% |
Earnings per share | -0.26 | 72.63% |
EBITDA | -31.14M | 70.06% |
Effective tax rate | -2.37% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 922.33M | -1.52% |
Total assets | 1.59B | 9.98% |
Total liabilities | 712.42M | 7.64% |
Total equity | 878.52M | — |
Shares outstanding | 132.02M | — |
Price to book | 23.92 | — |
Return on assets | -6.33% | — |
Return on capital | -7.48% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -31.59M | 71.02% |
Cash from operations | 51.79M | 274.37% |
Cash from investing | 42.54M | -47.67% |
Cash from financing | 1.72M | -99.27% |
Net change in cash | 96.05M | -66.60% |
Free cash flow | 40.19M | 1,066.44% |
About
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
3,288
